Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt

Takeda Pharmaceutical Co. is weighing the sale of a Shire Plc eye care business once its $62 billion purchase of the U.K.-listed biotech firm is completed, as it seeks ways to cut the debt raised to fund the deal, people familiar with the matter said.